Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007032362 - SUBSTITUTED CYCLOALKENE DERIVATIVE

Publication Number WO/2007/032362
Publication Date 22.03.2007
International Application No. PCT/JP2006/318103
International Filing Date 13.09.2006
IPC
C07C 311/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
14Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
A61K 31/215 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
A61K 31/336 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
A61K 31/343 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
343condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/357 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
357having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/385 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
385having two or more sulfur atoms in the same ring
CPC
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
39General protective or antinoxious agents
02Antidotes
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07C 2601/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2601Systems containing only non-condensed rings
12with a six-membered ring
16the ring being unsaturated
C07C 2602/50
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
2602Systems containing two condensed rings
50Spiro compounds
C07C 311/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
14Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
Applicants
  • DAIICHI SANKYO COMPANY, LIMITED [JP]/[JP] (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • KIMURA, Tomio (UsOnly)
  • OHKAWA, Nobuyuki (UsOnly)
  • NAGASAKI, Takayoshi (UsOnly)
  • SUGIDACHI, Atsuhiro [JP]/[JP] (UsOnly)
  • ANDO, Osamu [JP]/[JP] (UsOnly)
Inventors
  • KIMURA, Tomio
  • OHKAWA, Nobuyuki
  • NAGASAKI, Takayoshi
  • SUGIDACHI, Atsuhiro
  • ANDO, Osamu
Agents
  • YAGUCHI, Toshiaki
Priority Data
2005-26750414.09.2005JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) SUBSTITUTED CYCLOALKENE DERIVATIVE
(FR) DÉRIVÉ DE CYCLOALCÈNE SUBSTITUÉ
(JA) 置換シクロアルケン誘導体
Abstract
(EN)
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as hyperproduction of an inflammatory mediator caused by them, a pharmacologically acceptable salt thereof, a method for producing the same, and a pharmaceutical containing the cycloalkene derivative as an active ingredient, which is excellent in prevention and/or treatment of a disease such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure or the like). General formula (I): {In the formula, X and Y represent a group which forms the ring A with the carbon atom of the ring B to which X and Y are bound or the like. l and m independently represent an integer of 0 to 3 and l+m is 1 to 3. R1 represents an aliphatic hydrocarbon group which may be substituted or the like. n represents an integer of 0 to 3. R2 represents a hydrogen atom, an alkyl group which may be substituted or the like, R3 represents a phenyl group which may be substituted or the like, and R5 represents a hydrogen atom, an alkyl group which may be substituted or the like.}
(FR)
L'invention a pour objet un dérivé de cycloalcène substitué représenté par la formule générale (I) lequel a un effet de suppression de la transduction du signal intracellulaire ou de l'activation cellulaire provoquées par une endotoxine et d'une réponse cellulaire telle que l'hyperproduction d'un médiateur inflammatoire provoquée par celles-ci ; un sel acceptable du point de vue pharmacologique de celui-ci ; un procédé servant à produire celui-ci ; et un produit pharmaceutique contenant le dérivé de cycloalcène comme ingrédient actif, lequel est excellent dans la prévention et/ou le traitement d'une maladie telle qu'une sepsie (un choc septique, une coagulation intravasculaire disséminée, une insuffisance d'organes multiples ou similaire). Formule générale (I) : {Dans la formule, X et Y représentent un groupe qui forme le cycle A avec l'atome de carbone du cycle B auquel X et Y sont liés ou similaire. l et m représentent chacun indépendamment un nombre entier de 0 à 3 et l + m vaut 1 à 3. R1 représente un groupe hydrocarboné aliphatique qui peut être substitué ou similaire. n représente un nombre entier de 0 à 3. R2 représente un atome d'hydrogène, un groupe alkyle qui peut être substitué ou similaire, R3 représente un groupe phényle qui peut être substitué ou similaire et R5 représente un atome d'hydrogène, un groupe alkyle qui peut être substitué ou similaire.}
(JA)
not available
Latest bibliographic data on file with the International Bureau